

Result of Share Purchase Plan Offer (SPP)

- \$119,500 in applications received at the issue price of 2.5 cents per share
- With an underwriting agreement for up to \$500,000, the placement of \$380,500 in shortfall will be subject to shareholder approval at an upcoming EGM

Bio-Gene Technology Limited (**ASX:BGT, Bio-Gene** or the **Company**), is pleased to announce that it has received \$119,500 in applications for 4,780,000 fully paid ordinary shares at the issue price of 2.5 cents per share under the 2026 Share Purchase Plan (**SPP**) which closed on 19 June 2026.

Eligible Shareholders who successfully applied for shares under the SPP are expected to be granted 2,390,000 SPP Options (exercise price of 3.5 cents per option, expiry date of 15 October 2027) (**SPP Options**) for no further cash consideration within 5 days of the Company obtaining approval for the grant of the SPP Options at an Extraordinary General Meeting (**EGM**) of shareholders expected to be held on or around 31 July 2026.

As announced on 26 May 2026, the Company entered into an underwriting agreement for up to \$500,000 of funds raised under the SPP with a 6% cash fee payable to the underwriter (Dr Choon Huat Lee). The shortfall of \$380,500 (15,220,000 fully paid ordinary shares and 7,610,000 free attaching SPP options) will be subject to shareholder approval being obtained at the proposed EGM.

Proceeds raised from the SPP and recent Placement will be used to fund Flavocide® regulatory enabling studies, increasing production of Qcide®, product development activities supporting the Company's commercial partnering arrangements, strategic projects, general working capital and costs of the raise.

An Appendix 2A in respect of the SPP shares issued has been lodged today.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and demand for natural insecticides. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health, animal health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.
